NRx Pharmaceuticals Leaders to Present at the H.C. Wainwright & Co. 24th Annual Global Investment Conference

Rhea-AI Summary

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) announced that CEO Stephen Willard and executives will provide a corporate update at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 9:00 AM ET. This presentation will cover the company’s progress, particularly focusing on NRX-101, a novel treatment for severe bipolar depression. NRX-101 has received FDA Breakthrough Therapy designation and is expected to begin its registration trial in Q4 2022. The event is accessible via webcast with a replay available for 30 days.

Company to Present Corporate Update During Investor Conference, Sept. 14, 2022, at 9:00am ET

RADNOR, Pa., Sept. 8, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, today announced its Chief Executive Officer, Stephen Willard, and other executive leaders will be presenting an update to the company's business at the H.C. Wainwright & Co. 24^th Annual Global Investment Conference.

Stephen Willard & NRXP Executives to Present Business Update at H.C. Wainwright & Co. 24th Annual Investor Conference

Webcast Presentation Details: 

Event:  H.C. Wainwright 24^th Annual Global Investment Conference
Date: Wednesday, September 14, 2022
Time: 9:00 a.m. Eastern Time
Link to register for the NRx Pharmaceuticals' presentation at the conference: 
CLICK HERE.  (A replay will be available on the NRx Pharmaceuticals website for thirty (30) days following the presentation at www.nrxpharma.com).

About NRX-101

Up to 50% of individuals with bipolar disorder attempt suicide over their lifetime, and estimates indicate that up to 20% may succumb to suicide. The only FDA-approved treatment for patients with bipolar depression and acute suicidal ideation & behavior (ASIB) remains electroconvulsive therapy (ECT).  Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect. NRX-101 is a patented, fixed dose combination of D-cycloserine and lurasidone, neither of which has shown addiction potential. Based on the results of a Phase II study, NRX-101 received Breakthrough Therapy designation (BTD) from the FDA for the Treatment of Severe Bipolar Depression in Patients with ASIB after initial stabilization with ketamine or other effective therapy.

NRX-101 is one of the first oral antidepressants currently in late-stage clinical studies targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, as well as PTSD and other indications. To date, NRX-101 is the only oral NMDA investigational medicine focused on bipolar depression in patients with acute and sub-acute suicidality.

NRx Pharmaceuticals expects to begin its registration trial for NRX-101 under a SPA in 4Q 2022. 

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc. draws upon decades of collective, scientific, and drug-development experience applying innovative science to known molecules to address very high unmet needs and bring improved health to patients. NRx Pharmaceuticals is led by executives who have held leadership roles at Lilly, Pfizer, and Novartis as well as major investment banking institutions. 

Cautionary Note Regarding Forward-Looking Statements

This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management.  

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise.  Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

CORPORATE CONTACT
Molly Cogan
Sr. Director, Global Communications & Government Affairs
mcogan@nrxpharma.com

INVESTOR RELATIONS
Suzanne Messere
Investor Relations
suzanne.messere@sternir.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nrx-pharmaceuticals-leaders-to-present-at-the-hc-wainwright--co-24th-annual-global-investment-conference-301620084.html

SOURCE NRx Pharmaceuticals, Inc.

FAQ

What is the date of NRx Pharmaceuticals' presentation at the H.C. Wainwright Annual Global Investment Conference?

NRx Pharmaceuticals will present on September 14, 2022.

Who will present the corporate update for NRx Pharmaceuticals at the conference?

CEO Stephen Willard and other executives will present the update.

What is NRX-101 and its significance for NRx Pharmaceuticals?

NRX-101 is a treatment for severe bipolar depression that has received FDA Breakthrough Therapy designation.

When does NRx Pharmaceuticals expect to begin its registration trial for NRX-101?

The registration trial for NRX-101 is expected to begin in Q4 2022.

Where can I access the webcast of NRx Pharmaceuticals' presentation?

The webcast can be accessed through the registration link provided for the conference.